CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a Phase I/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL).
Epistemonikos ID: 7eded4e94a05014b15344bf866c1fd85aa449d4d
First added on: Oct 23, 2026